Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5147-5152

  Schlegel, Kelly Ann S ^a   Yang, Zhi Qiang ^a   Reger, Thomas S ^a   Shu, Youheng ^a   Cube, Rowena ^a   Rittle, Kenneth E ^a   Bondiskey, Phung ^a   Bock, Mark G ^a   Hartman, George D ^a   Tang, Cuyue ^a   Ballard, Jeanine ^a   Kuo, Yuhsin ^a   Prueksaritanont, Thomayant ^a   Nuss, Cindy E ^a   Doran, Scott M ^a   Fox, Steven V ^a   Garson, Susan L ^a   Kraus, Richard L ^a   Li, Yuxing ^a   Uebele, Victor N ^a   Renger, John J ^a   Barrow, James C ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Calcium channel antagonists; Epilepsy; Quinazolin 2 ones; T Type calcium channel

Indexed keywords

1,2,3,5 TETRAHYDROIMIDAZO[2,1 B]QUINAZOLIN 2 ONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; PREGNANE X RECEPTOR; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; NONHUMAN; RAT; SEIZURE; SLEEP; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DISCOVERY; HAPLORHINI; HUMANS; QUINAZOLINONES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77955654799     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.010     Document Type: Article

References (29)

1. G.W. Zamponi Voltage-Gated Calcium Channels 2005 Kluwer Academic/Plenum
2. R.W. Tsien, and D.B. Wheeler E. Carafoli, C. Klee, Calcium as a Cellular Regulator 1999 Oxford University Press New York 171 199
3. E.M. Talley, L.L. Cribbs, J.H. Lee, A. Daud, E. Perez-Reyes, and D. Bayliss J. Neurosci. 19 1999 1895
4. R.R. Llinas, and M. Steriade J. Neurophysiol. 95 2006 3297
5. V. Crunelli, D.W. Cope, and S.W. Hughes Cell Calcium 40 2006 175
6. D. Varela, H. Khosravani, S.E. Heron, C. Bladen, T.C. Williams, M. Newman, S.F. Berkovic, I.E. Scheffer, J.C. Mulley, and G.W. Zamponi Biophysical Society Meeting Abstracts Biophys. J. 2007 2868
7. Y. Zhang, R.R. Llinas, and J.E. Lisman Front Neural Circuits 3 2009 20
8. S.M. Todorovic, and V. Jevtovic-Todorovic CNS Neurol. Disord.: Drug Targets 5 2006 639
9. L. Cueni, M. Canepari, J.P. Adelman, and A. Luthi Pflug. Arch. Eur. J. Phy. 457 2009 1161
10. T. Bessaih, N. Leresche, and R.C. Lambert Proc. Natl Acad. Sci. U.S.A. 105 2008 11376
11. J.P. Clozel, E.A. Ertel, and S.I. Ertel J. Hypertens. 15 1997 S17
12. G. Mehrke, V. Flockerzi, and F. Hofmann J. Pharmacol. Exp. Ther. 271 1994 1483
13. I. Bezprozvanny, and R.W. Tsien Mol. Pharmacol. 48 1995 540
14. S. Moosmang, N. Haider, B. Bruderl, A. Welling, and F. Hofmann Circ. Res. 98 2006 105
15. W.D. Shipe, J.C. Barrow, Z.-Q. Yang, C.W. Lindsley, F.V. Yang, K.-A.S. Schlegel, Y. Shu, K.E. Rittle, M.G. Bock, G.D. Hartman, C. Tang, J.E. Ballard, Y. Kuo, E.D. Adarayan, T. Prueksaritanont, M.M. Zrada, V.N. Uebele, C.E. Nuss, T.M. Connolly, S.M. Doran, S.V. Fox, R.L. Kraus, M.J. Marino, V.K. Gratifelds, H.M. Vargas, P.B. Bunting, M. Hasbun-Manning, R.M. Evans, K.S. Koblan, and J.J. Renger J. Med. Chem. 51 2008 3692
16. Z.-Q. Yang, J.C. Barrow, W.D. Shipe, K.-A.S. Schlegel, Y.S. Shu, F.V. Yang, C.W. Lindsley, K.E. Rittle, M.G. Bock, G.D. Hartman, V.N. Uebele, C.E. Nuss, S.V. Fox, R.L. Kraus, S.M. Doran, T.M. Connolly, C.Y. Tang, J.E. Ballard, Y.S. Kuo, E.D. Adarayan, T. Prueksaritanont, M.M. Zrada, M.J. Marino, V.K. Graufelds, A.G. DiLella, I.J. Reynolds, H.M. Vargas, P.B. Bunting, R.F. Woltmann, M.M. Magee, K.S. Koblan, and J.J. Renger J. Med. Chem. 51 2008 6471
17. J.C. Barrow, K.E. Rittle, T.S. Reger, Z.-Q. Yang, P. Bondiskey, G.B. McGaughey, M.G. Bock, G.D. Hartman, C.Y. Tang, J.E. Ballard, Y.S. Kuo, T. Prueksaritanont, C.E. Nuss, S.M. Doran, S.V. Fox, S.L. Garson, R.L. Kraus, Y. Li, M.J. Marino, V.K. Graufelds, V.N. Uebele, and J.J. Renger ACS Med. Chem. Lett. 1 2010 75
18. T.J. Tucker, T.A. Lyle, C.M. Wiscount, S.F. Britcher, S.D. Young, W.M. Sanders, W.C. Lumma, M.E. Goldman, J.A. Obrien, R.G. Ball, C.F. Homnick, W.A. Schleif, E.A. Emini, J.R. Huff, and P.S. Anderson J. Med. Chem. 37 1994 2437
19. V.N. Uebele, C.E. Nuss, S.V. Fox, S.L. Garson, R. Cristescu, S.M. Doran, R.L. Kraus, V.P. Santarelli, Y. Li, J.C. Barrow, Z.Q. Yang, K.A. Schlegel, K.E. Rittle, T.S. Reger, R.A. Bednar, W. Lemaire, F.A. Mullen, J.E. Ballard, C. Tang, G. Dai, O.B. McManus, K.S. Koblan, and J.J. Renger Cell Biochem. Biophys. 55 2009 81
20. N.A. Magnus, P.N. Confalone, L. Storace, M. Patel, C.C. Wood, W.P. Davis, and R.L. Parsons J. Org. Chem. 68 2003 754
21. The synthesis of 4,4-disubstituted quinazolinones has been reported in the following patent literature: WO2009009015 and WO2006098969.
22. M. Sinz, S. Kim, Z. Zhu, T. Chen, M. Anthony, K. Dickinson, and A.D. Rodrigues Curr. Drug Metab. 7 2006 375
23. Based on Ref. 22 and in house data, the following guidelines are used to determine the potential for clinical drug-drug interactions. Using % activation (compared to the positive control Rifampin), the criteria for having a high potential for clinical drug-drug interaction is defined as a value of >40%, between 15% and 40% for moderate potential, and <15% as having a low potential.
24. Y.D. Gao, S.H. Olson, J.M. Balkovec, Y. Zhu, I. Royo, J. Yabut, R. Evers, E.Y. Tan, W. Tang, D.P. Hartley, and R.T. Mosley Xenobiotica 37 2007 124
25. For metabolic stability assay, compounds (1 μM) were incubated with human liver microsomes (0.2 mg protein/mL) in the presence of NADPH cofactor for 30 or 60 min at 37 °C.
26. Compound 45 is a single, active enantiomer. All in vitro and in vivo data included for 45 was collected on the active enantiomer.
27. J.H. Hochman, N. Pudvah, J. Qiu, M. Yamazaki, C. Tang, J.H. Lin, and T. Prueksaritanont Pharm. Res. 21 2004 1686 1691
28. A.M.L. Coenen, W.H.I.M. Drinkenburg, M. Inoue, and E.L.J.M. Vanluijtelaar Epilepsy Res. 12 1992 75
29. V.N. Uebele, A.L. Gotter, C.E. Nuss, R.L. Kraus, S.M. Doran, S.L. Garson, D.R. Reiss, Y.X. Li, J.C. Barrow, T.S. Reger, Z.Q. Yang, J.E. Ballard, C.Y. Tang, J.M. Metzger, S.P. Wang, K.S. Koblan, and J.J. Renger J. Clin. Invest. 119 2009 1659